ALT
Price
$7.66
Change
-$0.22 (-2.79%)
Updated
Sep 16, 02:58 PM (EDT)
50 days until earnings call
EDIT
Price
$3.82
Change
-$0.13 (-3.29%)
Updated
Sep 16, 03:13 PM (EDT)
51 days until earnings call
Ad is loading...

ALT vs EDIT

Header iconALT vs EDIT Comparison
Open Charts ALT vs EDITBanner chart's image
Altimmune
Price$7.66
Change-$0.22 (-2.79%)
Volume$2.61K
CapitalizationN/A
Editas Medicine
Price$3.82
Change-$0.13 (-3.29%)
Volume$734
CapitalizationN/A
View a ticker or compare two or three
ALT vs EDIT Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALT vs. EDIT commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a StrongBuy and EDIT is a StrongBuy.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (ALT: $7.88 vs. EDIT: $3.95)
Brand notoriety: ALT and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 203% vs. EDIT: 81%
Market capitalization -- ALT: $560.04M vs. EDIT: $325.78M
ALT [@Biotechnology] is valued at $560.04M. EDIT’s [@Biotechnology] market capitalization is $325.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $606.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 5 bearish.
  • EDIT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а +27.10% price change this week, while EDIT (@Biotechnology) price change was +10.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.24%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

ALT is expected to report earnings on Nov 05, 2024.

EDIT is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+2.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($560M) has a higher market cap than EDIT($326M). ALT YTD gains are higher at: -29.956 vs. EDIT (-61.007). ALT has higher annual earnings (EBITDA): -100.91M vs. EDIT (-207.21M). EDIT has more cash in the bank: 279M vs. ALT (165M). ALT has less debt than EDIT: ALT (1.86M) vs EDIT (38.7M). EDIT has higher revenues than ALT: EDIT (67M) vs ALT (409K).
ALTEDITALT / EDIT
Capitalization560M326M172%
EBITDA-100.91M-207.21M49%
Gain YTD-29.956-61.00749%
P/E RatioN/AN/A-
Revenue409K67M1%
Total Cash165M279M59%
Total Debt1.86M38.7M5%
FUNDAMENTALS RATINGS
ALT vs EDIT: Fundamental Ratings
ALT
EDIT
OUTLOOK RATING
1..100
1826
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3664
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for ALT (86) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew somewhat faster than ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (77) in the Miscellaneous Commercial Services industry is in the same range as EDIT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (36) in the Miscellaneous Commercial Services industry is in the same range as EDIT (64) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as EDIT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTEDIT
RSI
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 20 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
86%
Aroon
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIGTX14.720.27
+1.87%
The Texas I
FAFSX32.280.39
+1.22%
Fidelity Advisor Financials M
KLCAX21.410.09
+0.42%
Federated Hermes Kaufmann Large Cap A
HDDVX16.700.05
+0.30%
Janus Henderson Responsible Intl Div D
HHHRX16.810.03
+0.18%
Hartford Schroders Emerging Mkts Eq R3

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with EDIT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+10.99%
EDIT - ALT
43%
Loosely correlated
+5.33%
VKTX - ALT
42%
Loosely correlated
+6.24%
INZY - ALT
42%
Loosely correlated
+6.76%
PLRX - ALT
42%
Loosely correlated
+1.35%
KRYS - ALT
41%
Loosely correlated
+3.04%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+5.33%
NTLA - EDIT
74%
Closely correlated
+6.77%
BEAM - EDIT
67%
Closely correlated
+7.79%
CRSP - EDIT
67%
Closely correlated
+6.65%
PRME - EDIT
54%
Loosely correlated
+0.99%
ALLO - EDIT
53%
Loosely correlated
+11.28%
More